On Aug. 5, 2020, Pfizer Canada and BioNTech announced an agreement with the Government of Canada to supply their BNT162 mRNA-based vaccine candidate against SARS-CoV2, subject to clinical success and Health Canada approval. Financial details of the agreement were not disclosed.